west pharmaceutical services cornwall limited
west pharmaceutical services cornwall limited Company Information
Company Number
00930319
Next Accounts
Sep 2025
Industry
Manufacture of basic pharmaceutical products
Shareholders
west pharmaceutical services group ltd
Group Structure
View All
Contact
Registered Address
c/o corporation service company, 5 churchill place, 10th floor, london, E14 5HU
Website
www.westpharma.comwest pharmaceutical services cornwall limited Estimated Valuation
Pomanda estimates the enterprise value of WEST PHARMACEUTICAL SERVICES CORNWALL LIMITED at £112.8m based on a Turnover of £53.6m and 2.11x industry multiple (adjusted for size and gross margin).
west pharmaceutical services cornwall limited Estimated Valuation
Pomanda estimates the enterprise value of WEST PHARMACEUTICAL SERVICES CORNWALL LIMITED at £61.2m based on an EBITDA of £7.2m and a 8.5x industry multiple (adjusted for size and gross margin).
west pharmaceutical services cornwall limited Estimated Valuation
Pomanda estimates the enterprise value of WEST PHARMACEUTICAL SERVICES CORNWALL LIMITED at £62.1m based on Net Assets of £32.8m and 1.89x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
West Pharmaceutical Services Cornwall Limited Overview
West Pharmaceutical Services Cornwall Limited is a live company located in london, E14 5HU with a Companies House number of 00930319. It operates in the manufacture of basic pharmaceutical products sector, SIC Code 21100. Founded in April 1968, it's largest shareholder is west pharmaceutical services group ltd with a 100% stake. West Pharmaceutical Services Cornwall Limited is a mature, large sized company, Pomanda has estimated its turnover at £53.6m with healthy growth in recent years.
Upgrade for unlimited company reports & a free credit check
West Pharmaceutical Services Cornwall Limited Health Check
Pomanda's financial health check has awarded West Pharmaceutical Services Cornwall Limited a 5 rating. We use a traffic light system to show it exceeds the industry average on 9 measures and has 3 areas for improvement. Company Health Check FAQs
9 Strong
0 Regular
3 Weak
Size
annual sales of £53.6m, make it larger than the average company (£37.1m)
£53.6m - West Pharmaceutical Services Cornwall Limited
£37.1m - Industry AVG
Growth
3 year (CAGR) sales growth of 8%, show it is growing at a faster rate (5.4%)
8% - West Pharmaceutical Services Cornwall Limited
5.4% - Industry AVG
Production
with a gross margin of 15.7%, this company has a higher cost of product (38.8%)
15.7% - West Pharmaceutical Services Cornwall Limited
38.8% - Industry AVG
Profitability
an operating margin of 11.2% make it more profitable than the average company (6.9%)
11.2% - West Pharmaceutical Services Cornwall Limited
6.9% - Industry AVG
Employees
with 208 employees, this is above the industry average (108)
208 - West Pharmaceutical Services Cornwall Limited
108 - Industry AVG
Pay Structure
on an average salary of £46.8k, the company has a lower pay structure (£67.7k)
£46.8k - West Pharmaceutical Services Cornwall Limited
£67.7k - Industry AVG
Efficiency
resulting in sales per employee of £257.5k, this is less efficient (£454k)
£257.5k - West Pharmaceutical Services Cornwall Limited
£454k - Industry AVG
Debtor Days
it gets paid by customers after 30 days, this is earlier than average (56 days)
30 days - West Pharmaceutical Services Cornwall Limited
56 days - Industry AVG
Creditor Days
its suppliers are paid after 16 days, this is quicker than average (34 days)
16 days - West Pharmaceutical Services Cornwall Limited
34 days - Industry AVG
Stock Days
it holds stock equivalent to 25 days, this is less than average (104 days)
25 days - West Pharmaceutical Services Cornwall Limited
104 days - Industry AVG
Cash Balance
has cash to cover current liabilities for 122 weeks, this is more cash available to meet short term requirements (10 weeks)
122 weeks - West Pharmaceutical Services Cornwall Limited
10 weeks - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 21.6%, this is a lower level of debt than the average (44.6%)
21.6% - West Pharmaceutical Services Cornwall Limited
44.6% - Industry AVG
WEST PHARMACEUTICAL SERVICES CORNWALL LIMITED financials
West Pharmaceutical Services Cornwall Limited's latest turnover from December 2023 is £53.6 million and the company has net assets of £32.8 million. According to their latest financial statements, West Pharmaceutical Services Cornwall Limited has 208 employees and maintains cash reserves of £19.2 million as reported in the balance sheet.
Data source: Companies House, Pomanda Estimates
| Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | 53,566,000 | 54,924,000 | 51,456,000 | 42,051,000 | 56,233,000 | 47,606,000 | 46,333,000 | 39,914,000 | 29,987,000 | 24,844,000 | 29,690,000 | 34,596,000 | 33,223,000 | 39,025,000 | 38,633,000 |
| Other Income Or Grants | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost Of Sales | 45,161,000 | 43,976,000 | 42,699,000 | 37,733,000 | 52,937,000 | 43,056,000 | 40,366,000 | 36,428,000 | 26,615,000 | 22,588,000 | 25,838,000 | 30,210,000 | 28,340,000 | 35,038,000 | 33,844,000 |
| Gross Profit | 8,405,000 | 10,948,000 | 8,757,000 | 4,318,000 | 3,296,000 | 4,550,000 | 5,967,000 | 3,486,000 | 3,372,000 | 2,256,000 | 3,852,000 | 4,386,000 | 4,883,000 | 3,987,000 | 4,789,000 |
| Admin Expenses | 2,411,000 | 4,603,000 | 2,784,000 | 1,800,000 | 1,460,000 | 1,856,000 | 2,484,000 | 2,394,000 | 2,658,000 | 1,648,000 | 10,322,000 | 2,534,000 | 2,511,000 | 2,624,000 | 2,072,000 |
| Operating Profit | 5,994,000 | 6,345,000 | 5,973,000 | 2,518,000 | 1,836,000 | 2,694,000 | 3,483,000 | 1,092,000 | 714,000 | 608,000 | -6,470,000 | 1,852,000 | 2,372,000 | 1,363,000 | 2,717,000 |
| Interest Payable | 30,000 | 32,000 | 103,000 | 117,000 | 165,000 | 35,000 | 33,000 | 124,000 | 16,000 | 33,000 | 70,000 | 27,000 | 31,000 | 22,000 | 65,000 |
| Interest Receivable | 546,000 | 49,000 | 2,000 | 23,000 | 52,000 | 75,000 | 106,000 | 121,000 | 134,000 | 148,000 | 169,000 | 160,000 | 96,000 | 2,000 | 9,000 |
| Pre-Tax Profit | 6,510,000 | 6,362,000 | 5,872,000 | 2,424,000 | 1,723,000 | 3,313,000 | 3,531,000 | 1,293,000 | 899,000 | -228,000 | -7,266,000 | 36,000 | 1,763,000 | -441,000 | 2,661,000 |
| Tax | -746,000 | -887,000 | -748,000 | -928,000 | -671,000 | -566,000 | -604,000 | -441,000 | -763,000 | -21,000 | 806,000 | -787,000 | -638,000 | -243,000 | -1,204,000 |
| Profit After Tax | 5,764,000 | 5,475,000 | 5,124,000 | 1,496,000 | 1,052,000 | 2,747,000 | 2,927,000 | 852,000 | 136,000 | -249,000 | -6,460,000 | -751,000 | 1,125,000 | -684,000 | 1,457,000 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3,000,000 | 0 | 3,600,000 | 0 | 0 |
| Retained Profit | 5,764,000 | 5,475,000 | 5,124,000 | 1,496,000 | 1,052,000 | 2,747,000 | 2,927,000 | 852,000 | 136,000 | -249,000 | -9,460,000 | -751,000 | -2,475,000 | -684,000 | 1,457,000 |
| Employee Costs | 9,737,000 | 9,967,000 | 8,631,000 | 6,625,000 | 6,190,000 | 6,212,000 | 6,089,000 | 5,550,000 | 5,534,000 | 14,745,000 | 9,968,000 | 10,698,000 | 11,359,000 | 10,356,000 | |
| Number Of Employees | 208 | 215 | 186 | 187 | 169 | 161 | 159 | 157 | 153 | 154 | 168 | 313 | 361 | 416 | 403 |
| EBITDA* | 7,208,000 | 7,281,000 | 6,874,000 | 3,400,000 | 2,646,000 | 3,557,000 | 4,202,000 | 1,830,000 | 1,592,000 | 1,607,000 | -5,604,000 | 2,947,000 | 4,663,000 | 3,672,000 | 4,896,000 |
* Earnings Before Interest, Tax, Depreciation and Amortisation
| Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tangible Assets | 11,405,000 | 10,066,000 | 8,253,000 | 7,913,000 | 6,579,000 | 6,440,000 | 6,887,000 | 6,371,000 | 6,093,000 | 6,143,000 | 6,318,000 | 7,056,000 | 9,700,000 | 14,170,000 | 15,588,000 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 54,000 |
| Investments & Other | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Debtors (Due After 1 year) | 0 | 0 | 0 | 0 | 0 | 526,000 | 995,000 | 1,639,000 | 1,914,000 | 2,041,000 | 2,436,000 | 2,828,000 | 2,296,000 | 0 | 0 |
| Total Fixed Assets | 11,405,000 | 10,066,000 | 8,253,000 | 7,913,000 | 6,579,000 | 6,966,000 | 7,882,000 | 8,010,000 | 8,007,000 | 8,184,000 | 8,754,000 | 9,884,000 | 11,996,000 | 14,170,000 | 15,642,000 |
| Stock & work in progress | 3,142,000 | 3,070,000 | 1,520,000 | 2,326,000 | 1,576,000 | 2,754,000 | 1,609,000 | 1,812,000 | 1,962,000 | 1,461,000 | 1,521,000 | 3,946,000 | 2,729,000 | 2,772,000 | 2,982,000 |
| Trade Debtors | 4,491,000 | 5,364,000 | 4,958,000 | 3,989,000 | 5,328,000 | 5,344,000 | 5,658,000 | 4,279,000 | 4,149,000 | 3,001,000 | 2,924,000 | 3,730,000 | 3,573,000 | 4,010,000 | 3,434,000 |
| Group Debtors | 3,259,000 | 884,000 | 3,870,000 | 0 | 897,000 | 1,305,000 | 382,000 | 1,256,000 | 1,294,000 | 1,272,000 | 805,000 | 1,320,000 | 1,806,000 | 1,396,000 | 1,267,000 |
| Misc Debtors | 402,000 | 485,000 | 983,000 | 5,354,000 | 3,491,000 | 621,000 | 819,000 | 868,000 | 739,000 | 702,000 | 1,274,000 | 588,000 | 469,000 | 376,000 | 405,000 |
| Cash | 19,192,000 | 19,963,000 | 12,877,000 | 6,286,000 | 9,884,000 | 8,857,000 | 7,713,000 | 2,750,000 | 498,000 | 1,439,000 | 1,137,000 | 1,844,000 | 2,032,000 | 3,777,000 | 5,357,000 |
| misc current assets | 0 | 0 | 0 | 0 | 0 | 2,893,000 | 3,430,000 | 4,410,000 | 4,018,000 | 4,900,000 | 4,792,000 | 3,944,000 | 4,085,000 | 3,657,000 | 3,211,000 |
| total current assets | 30,486,000 | 29,766,000 | 24,208,000 | 17,955,000 | 21,176,000 | 21,774,000 | 19,611,000 | 15,375,000 | 12,660,000 | 12,775,000 | 12,453,000 | 15,372,000 | 14,694,000 | 15,988,000 | 16,656,000 |
| total assets | 41,891,000 | 39,832,000 | 32,461,000 | 25,868,000 | 27,755,000 | 28,740,000 | 27,493,000 | 23,385,000 | 20,667,000 | 20,959,000 | 21,207,000 | 25,256,000 | 26,690,000 | 30,158,000 | 32,298,000 |
| Bank overdraft | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Bank loan | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Trade Creditors | 2,008,000 | 1,368,000 | 1,051,000 | 1,101,000 | 1,251,000 | 1,018,000 | 842,000 | 570,000 | 690,000 | 842,000 | 799,000 | 1,108,000 | 1,690,000 | 1,451,000 | 1,881,000 |
| Group/Directors Accounts | 2,842,000 | 3,754,000 | 4,919,000 | 0 | 3,612,000 | 5,437,000 | 5,919,000 | 3,540,000 | 1,918,000 | 2,040,000 | 2,729,000 | 1,642,000 | 1,394,000 | 1,698,000 | 4,863,000 |
| other short term finances | 0 | 49,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| hp & lease commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other current liabilities | 3,283,000 | 7,262,000 | 4,793,000 | 3,920,000 | 2,025,000 | 1,346,000 | 1,621,000 | 1,768,000 | 1,501,000 | 1,491,000 | 1,011,000 | 1,696,000 | 1,953,000 | 2,834,000 | 2,479,000 |
| total current liabilities | 8,133,000 | 12,433,000 | 10,763,000 | 5,021,000 | 6,888,000 | 7,801,000 | 8,382,000 | 5,878,000 | 4,109,000 | 4,373,000 | 4,539,000 | 4,446,000 | 5,037,000 | 5,983,000 | 9,223,000 |
| loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| hp & lease commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accruals and Deferred Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other liabilities | 0 | 0 | 0 | 0 | 0 | 5,686,000 | 7,043,000 | 10,177,000 | 6,227,000 | 7,507,000 | 7,085,000 | 0 | 0 | 0 | 0 |
| provisions | 921,000 | 326,000 | 100,000 | 6,778,000 | 6,510,000 | 0 | 0 | 0 | 0 | 0 | 0 | 1,645,000 | 1,737,000 | 1,784,000 | 0 |
| total long term liabilities | 921,000 | 326,000 | 100,000 | 6,778,000 | 6,510,000 | 5,686,000 | 7,043,000 | 10,177,000 | 6,227,000 | 7,507,000 | 7,085,000 | 1,645,000 | 1,737,000 | 1,784,000 | 0 |
| total liabilities | 9,054,000 | 12,759,000 | 10,863,000 | 11,799,000 | 13,398,000 | 13,487,000 | 15,425,000 | 16,055,000 | 10,336,000 | 11,880,000 | 11,624,000 | 6,091,000 | 6,774,000 | 7,767,000 | 9,223,000 |
| net assets | 32,837,000 | 27,073,000 | 21,598,000 | 14,069,000 | 14,357,000 | 15,253,000 | 12,068,000 | 7,330,000 | 10,331,000 | 9,079,000 | 9,583,000 | 19,165,000 | 19,916,000 | 22,391,000 | 23,075,000 |
| total shareholders funds | 32,837,000 | 27,073,000 | 21,598,000 | 14,069,000 | 14,357,000 | 15,253,000 | 12,068,000 | 7,330,000 | 10,331,000 | 9,079,000 | 9,583,000 | 19,165,000 | 19,916,000 | 22,391,000 | 23,075,000 |
| Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | |||||||||||||||
| Operating Profit | 5,994,000 | 6,345,000 | 5,973,000 | 2,518,000 | 1,836,000 | 2,694,000 | 3,483,000 | 1,092,000 | 714,000 | 608,000 | -6,470,000 | 1,852,000 | 2,372,000 | 1,363,000 | 2,717,000 |
| Depreciation | 1,214,000 | 936,000 | 901,000 | 882,000 | 810,000 | 863,000 | 719,000 | 738,000 | 878,000 | 999,000 | 866,000 | 1,095,000 | 2,291,000 | 2,305,000 | 2,163,000 |
| Amortisation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4,000 | 16,000 |
| Tax | -746,000 | -887,000 | -748,000 | -928,000 | -671,000 | -566,000 | -604,000 | -441,000 | -763,000 | -21,000 | 806,000 | -787,000 | -638,000 | -243,000 | -1,204,000 |
| Stock | 72,000 | 1,550,000 | -806,000 | 750,000 | -1,178,000 | 1,145,000 | -203,000 | -150,000 | 501,000 | -60,000 | -2,425,000 | 1,217,000 | -43,000 | -210,000 | 2,982,000 |
| Debtors | 1,419,000 | -3,078,000 | 468,000 | -373,000 | 1,920,000 | -58,000 | -188,000 | -54,000 | 1,080,000 | -423,000 | -1,027,000 | 322,000 | 2,362,000 | 676,000 | 5,106,000 |
| Creditors | 640,000 | 317,000 | -50,000 | -150,000 | 233,000 | 176,000 | 272,000 | -120,000 | -152,000 | 43,000 | -309,000 | -582,000 | 239,000 | -430,000 | 1,881,000 |
| Accruals and Deferred Income | -3,979,000 | 2,469,000 | 873,000 | 1,895,000 | 679,000 | -275,000 | -147,000 | 267,000 | 10,000 | 480,000 | -685,000 | -257,000 | -881,000 | 355,000 | 2,479,000 |
| Deferred Taxes & Provisions | 595,000 | 226,000 | -6,678,000 | 268,000 | 6,510,000 | 0 | 0 | 0 | 0 | 0 | -1,645,000 | -92,000 | -47,000 | 1,784,000 | 0 |
| Cash flow from operations | 2,227,000 | 10,934,000 | 609,000 | 4,108,000 | 8,655,000 | 1,805,000 | 4,114,000 | 1,740,000 | -894,000 | 2,592,000 | -3,985,000 | -310,000 | 1,017,000 | 4,672,000 | -36,000 |
| Investing Activities | |||||||||||||||
| capital expenditure | |||||||||||||||
| Change in Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| cash flow from investments | |||||||||||||||
| Financing Activities | |||||||||||||||
| Bank loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Group/Directors Accounts | -912,000 | -1,165,000 | 4,919,000 | -3,612,000 | -1,825,000 | -482,000 | 2,379,000 | 1,622,000 | -122,000 | -689,000 | 1,087,000 | 248,000 | -304,000 | -3,165,000 | 4,863,000 |
| Other Short Term Loans | -49,000 | 49,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long term loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hire Purchase and Lease Commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other long term liabilities | 0 | 0 | 0 | 0 | -5,686,000 | -1,357,000 | -3,134,000 | 3,950,000 | -1,280,000 | 422,000 | 7,085,000 | 0 | 0 | 0 | 0 |
| share issue | |||||||||||||||
| interest | 516,000 | 17,000 | -101,000 | -94,000 | -113,000 | 40,000 | 73,000 | -3,000 | 118,000 | 115,000 | 99,000 | 133,000 | 65,000 | -20,000 | -56,000 |
| cash flow from financing | -445,000 | -1,099,000 | 7,223,000 | -5,490,000 | -9,572,000 | -1,361,000 | 1,129,000 | 1,716,000 | -168,000 | -407,000 | 8,149,000 | 381,000 | -239,000 | -3,185,000 | 26,425,000 |
| cash and cash equivalents | |||||||||||||||
| cash | -771,000 | 7,086,000 | 6,591,000 | -3,598,000 | 1,027,000 | 1,144,000 | 4,963,000 | 2,252,000 | -941,000 | 302,000 | -707,000 | -188,000 | -1,745,000 | -1,580,000 | 5,357,000 |
| overdraft | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| change in cash | -771,000 | 7,086,000 | 6,591,000 | -3,598,000 | 1,027,000 | 1,144,000 | 4,963,000 | 2,252,000 | -941,000 | 302,000 | -707,000 | -188,000 | -1,745,000 | -1,580,000 | 5,357,000 |
west pharmaceutical services cornwall limited Credit Report and Business Information
West Pharmaceutical Services Cornwall Limited Competitor Analysis
Perform a competitor analysis for west pharmaceutical services cornwall limited by selecting its closest rivals, whether from the MANUFACTURING sector, other large companies, companies in E14 area or any other competitors across 12 key performance metrics.
west pharmaceutical services cornwall limited Ownership
WEST PHARMACEUTICAL SERVICES CORNWALL LIMITED group structure
West Pharmaceutical Services Cornwall Limited has no subsidiary companies.
Ultimate parent company
WEST PHARMACEUTICAL SERVICES INC
#0035847
2 parents
WEST PHARMACEUTICAL SERVICES CORNWALL LIMITED
00930319
west pharmaceutical services cornwall limited directors
West Pharmaceutical Services Cornwall Limited currently has 5 directors. The longest serving directors include Mr Sean Parish (Mar 2014) and Mrs Kimberly MacKay (Jun 2024).
| officer | country | age | start | end | role |
|---|---|---|---|---|---|
| Mr Sean Parish | Singapore | 50 years | Mar 2014 | - | Director |
| Mrs Kimberly MacKay | United Kingdom | 59 years | Jun 2024 | - | Director |
| Mr Shay Kearns | United Kingdom | 47 years | Jun 2024 | - | Director |
| Mr Seamus Kilbane | United Kingdom | 60 years | Jun 2024 | - | Director |
| Mr David Greet | United Kingdom | 49 years | Jun 2024 | - | Director |
P&L
December 2023turnover
53.6m
-2%
operating profit
6m
-6%
gross margin
15.7%
-21.28%
turnover
Turnover, or revenue, is the amount of sales generated by a company within the financial year.
Balance Sheet
December 2023net assets
32.8m
+0.21%
total assets
41.9m
+0.05%
cash
19.2m
-0.04%
net assets
Total assets minus all liabilities
west pharmaceutical services cornwall limited company details
company number
00930319
Type
Private limited with Share Capital
industry
21100 - Manufacture of basic pharmaceutical products
incorporation date
April 1968
age
56
incorporated
UK
ultimate parent company
accounts
Full Accounts
last accounts submitted
December 2023
previous names
the west company (uk) limited (March 1999)
pharma-gummi (uk) limited (June 1995)
accountant
-
auditor
PKF FRANCIS CLARK
address
c/o corporation service company, 5 churchill place, 10th floor, london, E14 5HU
Bank
NATIONAL WESTMINSTER BANK PLC
Legal Advisor
-
west pharmaceutical services cornwall limited Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We did not find charges/mortgages relating to west pharmaceutical services cornwall limited.
west pharmaceutical services cornwall limited Capital Raised & Share Issues BETA
When a company issues new shares, e.g. to new investors following a funding round, it is required to notify Companies House within one month of making an allotment of shares.
Click to start generating capital raising & share issue transactions for WEST PHARMACEUTICAL SERVICES CORNWALL LIMITED. This can take several minutes, an email will notify you when this has completed.
west pharmaceutical services cornwall limited Companies House Filings - See Documents
| date | description | view/download |
|---|
